DeCure for Kidney neoplasm

A 1975 review of 150 patients with renal carcinoma found that 45 per cent were hospitalised with distant metastases or unresectable tumours at presentation. Among the 55 per cent considered theoretically curable, survival was markedly increased in patients with tumours smaller than 8 cm and with other features of low-stage disease. The authors stressed that patients can survive with tumour for long periods and that metastases may appear many years after surgery, so prognosis must be guarded and long follow-up is required to assess any therapy. A 2007 case report of a female patient with locally advanced renal carcinoma who underwent nephrectomy, chemotherapy and immunotherapy described rapid local and systemic progression despite all three modalities, illustrating the high aggressiveness of the tumour and the limited effect of those treatments.

A 2015 review states that kidney cancer accounts for over 3 per cent of new cancer diagnoses in men and around 2 per cent in women in the United Kingdom, and that in the United States approximately one-third of patients have metastatic disease at presentation. It notes that kidney cancer has a notoriously poor response to chemotherapy and radiotherapy, although treatment has evolved in the past decade. Two to three per cent of renal cancer cases are recognised as due to hereditary syndromes, with seven genes currently implicated. A 2022 review estimates that 5–8 per cent of renal tumours are hereditary, many inherited as autosomal-dominant, and summarises advances in targeted therapy for these syndromes.

A 2016 case report describes a 61-year-old man with both urothelial and squamous cell carcinoma of the renal pelvis, a rare entity that lacks the characteristic presentation of renal cell carcinoma and usually presents at an advanced stage. Urothelial carcinoma of the renal pelvis accounts for 7 per cent of all renal neoplasms, with squamous cell carcinoma forming a very small percentage. A 1979 report describes a 64-year-old man from whom four separate renal neoplasms were removed over eight months: two adenocarcinomas in the left nephrectomy specimen, plus a third adenocarcinoma and a papillary urothelial pelvic carcinoma resected segmentally from the right kidney; he died nine years later with local recurrence of the urothelial neoplasm but no metastatic carcinoma.

A 2001 review notes that classification of epithelial kidney tumours has changed considerably, with systems based on cytoplasmic characteristics and cytogenetic analysis leading to a more clinically significant pathological classification, though debate continues about their validity. A 1924 paper on multiple miliary adenomas of the kidney cortex reports that no uniformity of opinion had been reached on the histogenesis of renal neoplasms, with investigators agreeing only on a broad grouping into tumours of the capsule, cortex, and pelvis and collecting tubules. What remains missing across this literature is prospective data linking molecular subtypes to treatment outcomes, and any trial design that could test whether the targeted therapies described in the hereditary syndrome reviews alter survival in sporadic disease; the older case series provide no controlled evidence for any intervention.